Citations

Clear

941 citation(s) found for "Tefferi, A".

Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels
Tefferi, Ayalew , Nicolosi, Maura , Penna, Domenico , Mudireddy, Mythri , Hanson, Curtis A. , Gangat, Naseema , Pardanani, Animesh , Szuber, Natasha , Lasho, Terra L. , Ketterling, Rhett P.

Mayo Clinic

Blood Advances | September 14, 2018 | Volume: 2 | Issue: 15 | Pages: 1980-1984

10.1182/bloodadvances.2018018051 | PMID 30097464 Get It

Key PointsSerum albumin and cholesterol levels predict survival in primary myelofibrosis, independent of each other and contemporary risk models. The cachexia index, determined by serum albumin and cholesterol levels, might further refine current prognostic models in myelofibrosis.
Phase I study of lurbinectedin (PM11083) in patients with advanced AML and MDS.
Benton, Christopher B. , -Pavon, Jose Rodriguez Diaz, Maiti, Abhishek, Kwari, Monica, Siguero, Mariano, Tefferi, Ayalew , Pardanani, Animesh , Garcia‐Manero, Guillermo , Maiti, Abhishek , Daver, Naval , Ravandi, Farhad , Jain, Nitin , Alvarado, Yesid , Jabbour, Elias , Pierce, Sherry A. , Santos, Margarida A. , Martinez, Sara, Cortes, Jörge E. , Kantarjian, Hagop M.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: e18521-e18521

10.1200/jco.2017.35.15_suppl.e18521 Get It

e18521 Background: The FDA-approved drug trabectedin is a DNA minor groove binder (MGB) with activity against translocation-associated sarcomas. Lurbinectedin is a next-generation MGB, with activity against myeloid leukemia cells. A phase I clinical trial was initiated to determine recommended doses in MDS/AML. Further assessment of its safety, tolerability, and pharmacogenetics were studied. Methods: In total, 42 patients with relapsed/refractory MDS/AML received lurbinectedin, using a 3+3 study design. It was administered as a 1-hour IV infusion first at 3.5, 5, 6, and 7mg per dose on days 1 and 8. Subsequently, it was administered on days 1, 2, and 3, using 1, 1.5, 2, or 3mg per dose per patient. Results: Three patients had dose-limiting toxicities (DLTs), which were rhabdomyolysis (up to gr 4), hyperbilirubinemia (gr 3), and oral herpes (gr 3). All DLTs occurred in the 6 and 7mg cohorts. Adverse events included febrile neutropenia/infections (n = 3), GI (n = 6) and pulmonary (n = 2) toxicity, hyperhidrosis (n = 1), and QT prolongation (n = 1). Overall, 33 of 42 patients (79%) had reduction of blasts in peripheral blood (PB) or bone marrow (BM) at nadir, including 23 (55%) with > 50% reduction in PB blasts alone (n = 18) or both BM and PB blasts (n = 5). One patient had PR, 2 patients had morphologic leukemia-free survival, and most (n = 30) were discontinued for progressive disease. Early deaths occurred from disease-related causes, not attributable to lurbinectedin. Thirty-two patients treated at MD Anderson were analyzed for clinical characteristics and responses. Notably, among patients with follow-up bone marrow biopsy, those with a cytogenetic abnormality at chromosome 11q21-23 had significantly greater bone marrow blast reduction than those without such abnormality (change in percentage blasts: -31±14% [n = 4] vs. 8±8% [n = 16], respectively; P= 0.04). Conclusions: Lurbinectedin is generally safe and tolerated at dose levels tested. While no sustained remissions > 3 cycles were observed in these highest-risk patients, single-agent lurbinectedin was transiently leukemia suppressive for some patients, including some with abnormal chr11q or TP53 mutation. Rational combinations and situational uses of lurbinectedin are under consideration. Clinical trial information: NCT01314599.
Effect of echocardiogram prior to induction therapy for acute myeloid leukemia on detection of cardiac dysfunction and treatment modifications.
Yui, Jennifer , Mudireddy, Mythri , Patnaik, Mrinal M. , Gangat, Naseema , Al‐Kali, Aref , Elliott, Michelle A. , Hook, Carl C., Wolanskyj, Alexandra P., Pardanani, Animesh , Villarraga, Hector R. , Litzow, Mark R. , Tefferi, Ayalew , Begna, Kebede H. , Hogan, William J.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: e18514-e18514

10.1200/jco.2017.35.15_suppl.e18514 Get It

e18514 Background: Standard induction therapy for acute myeloid leukemia (AML) includes “cytarabine and anthracycline”. Anthracyclines are known to cause acute, subacute and chronic cardiac complications ( Lefrak , EA et al, Cancer 1973:32(2):302-314; Singal, PK et al, NEJM 1998;339(13):900-905). It is recommended to do base line cardiac function assessment with echocardiogram prior to induction therapy containing anthracycline. This study was done to find the frequency of changes made in avoiding anthracycline usage following this evaluation. Methods: The Mayo clinic data base was interrogated to identify patients with newly diagnosed AML who underwent echocardiogram prior to anthracycline containing induction chemotherapy. Echocardiogram results, including left ventricular ejection fraction (LVEF), diastolic dysfunction, valvular disease, and any resultant treatment alterations were reviewed. Results: Three hundred twenty six patients were identified. The median (range) age was 61 (17-82) years and 62% were male. The median (range) LVEF was 65% (30-87), and 3 (0.9%) patients had LVEF < 50% (range 30-47%). Of these 3 patients, 1 had 4 vessel CABG a decade ago, his EF was 46% and treated with full dose idarubicin; 2 of them presented with blastic crisis, 1 had EF 46% and improved to 51% after 5 days and then given daunorubicin, the other one had an EF of 30% and treated with 50% dose reduced cytarabine alone. Sixty five (23%) patients had previous chemotherapy or radiation exposure, including 24 (7.4 %) with previous anthracycline, 14 (4.3%) had prior radiation to the chest wall. No patient with previous chemotherapy or radiation exposure had a reduced LVEF. Conclusions: Echocardiography prior to anthracycline therapy rarely detects abnormal LVEF. Screening echo may be helpful in those presented with leukemic blastic crisis or had previous exposure to chemo-radiation.
Prognostic and therapeutic impact of cytogenetic abnormalities in patients with myelodysplastic/myeloproliferative neoplasms, unclassifiable.
Mangaonkar, Abhishek A. , Al‐Kali, Aref , Gangat, Naseema , Begna, Kebede H. , Elliott, Michelle A. , Zblewski, Darci, King, Rebecca L. , Litzow, Mark R. , Tefferi, Ayalew , Patnaik, Mrinal M. , Alkhateeb, Hassan B. , Hogan, William J. , Ketterling, Rhett P.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 7058-7058

10.1200/jco.2017.35.15_suppl.7058 Get It

7058 Background: The 2016 WHO classification includes myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U), as an MDS/MPN overlap syndrome not meeting criteria for well-defined entities such as CMML. No standard prognostication or treatment guidelines exist for such patients. Methods: We retrospectively identified MDS/MPN-U cases from 1990-2016 through our myeloid malignancies database. All bone marrow reports were reviewed to ensure compliance with 2016 WHO criteria. Clinical & cytogenetic parameters at diagnosis were assessed & compared with treatment outcomes. Results: Eighty nine patients met study criteria, with a median age of 69 years (range: 37-93); 58 (65%) males. Median follow-up was 22.2 months (range: 0-172), with 41 (46%) deaths & 13 (15%) leukemic transformations. Median OS was 24.8 months (range: 0-172). 43 (53%) patients had an abnormal karyotype, with common abnormalities being trisomy 8 (12%), complex karyotype (9%) & del (20q) (6%). Given the fewer types of abnormalities identified, the IPSS cytogenetic stratification was more effective than IPSS-R, with risk categorization including; 45 good (55%), 20 intermediate (25%) & 16 high risk (20%) respectively (8 unavailable). On univariate analysis, increased age (p = 0.05), decreased hemoglobin (p = 0.02), higher ANC (p = 0.03), circulating immature myeloid cells (p = 0.02), higher LDH (p = 0.009), absence of bone marrow ring sideroblasts (p = 0.001) & higher risk (intermediate & high) IPSS cytogenetic categories (p = 0.01) adversely impacted OS. In a multivariate model that included the aforementioned variables, higher risk IPSS cytogenetics retained a negative prognostic impact (p = 0.04). 28 patients received a median of 6 cycles (range: 1-21) of hypomethylating agent therapy (HMA), with an overall response rate of 18% (CR-3, PR-2). All responders had an abnormal karyotype (p = 0.01). However, HMA did not affect either OS or LFS. Conclusions: Intermediate & high risk IPSS cytogenetic categories independently & adversely impact survival in WHO defined MDS/MPN-U patients. HMA use did not impact OS; however, patients with abnormal karyotypes were more likely to respond.
Exploring the association between renal cell carcinoma (RCC) and myeloid malignancies.
Shenoy, Niraj , Mudireddy, Mythri , Costello, Brian A. , Leibovich, Bradley C. , Thompson, R. Houston, Pagliaro, Lance C. , Ördög, Tamás , Patnaik, Mrinal M. , Tefferi, Ayalew , Begna, Kebede H. , Shenoy, Niraj , Leung, Nelson , Witzig, Thomas E. , Ou, Fang‐Shu

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: e13073-e13073

10.1200/jco.2017.35.15_suppl.e13073 Get It

e13073 Background: We observed several patients with a personal history of both RCC and myeloid malignancy, and aimed to explore a possible association, especially given the similarity in their epigenetic landscape, with both being characterized by widespread aberrant hypermethylation (Hu C et al, CCR 2014; Jiang Y et al, Blood 2009). Methods: Mayo Clinic’s ‘Advanced Cohort Explorer’ database was used to identify patients with a history of both RCC and a myeloid malignancy - Acute Myelogenous Leukemia (AML), Myeloproliferative Neoplasms (MPN), Myelodysplastic syndromes (MDS) - and to determine the clinical characteristics. The incidence of MDS in patients ≥65 years with a history of RCC was compared to that in the general population ≥65 years (SEER- Medicare database) as well as the general patient population at Mayo Clinic, using one sample test of proportions. Results: A total of 59 patients were identified, with both biopsy proven RCC and a myeloid malignancy during their life time (12 AML, 9 MPN, 9 low risk MDS and 29 intermediate- high risk MDS). The cohort was characterized by marked male predominance (4.4: 1). Median age at RCC diagnosis was 64 years (range 37-87) and myeloid malignancy was 75 years (range 44-90). 46/59 patients had the RCC antecedent, 10/59 concurrent and 3/59 subsequent to the myeloid malignancy with a median time of myeloid malignancy diagnosis after RCC diagnosis of 7.7 years. For patients ≥65 years, the risk of developing MDS with a history of stage I/II RCC and nephrectomy was 5.26 times that of the general population based on the SEER-Medicare database (Cogle, Blood 2011)(395/100,000 vs 75/100,000; p value < 0.001), and 3.07 times that of the general population at Mayo Clinic (395/100,000 vs 128.4/100,000; p value < 0. 001). Conclusions: We observed an association between RCC and myeloid malignancies, particularly MDS; with a history of RCC conferring a substantially increased risk of developing MDS. We hypothesize that the perturbation of epigenetic landscape in the form of widespread hypermethylation may explain, in part, the association between the two malignancies; and aim to explore the potential aberrancy of epigenetic regulators in our patient cohort with a genomic, epigenomic and transcriptomic analysis.
The telomerase inhibitor imetelstat in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF) previously treated with Janus kinase (JAK) inhibitor: A phase 2, randomized study.
Tefferi, Ayalew , Gangat, Naseema , Niederwieser, Dietger , Droogenbroeck, Jan Van, Baer, Maria R. , Cervantes, Francisco , Sirhan, Shireen , Langlois, Angélique, Wan, Ying , Sherman, Laurie, Dougherty, Souria, Feller, Faye, Odenike, Olatoyosi , Kiladjian, Jean‐Jacques , Hoffman, Ronald , Finazzi, Guido , Gotlib, Jason , Apperley, Jane F.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS7079-TPS7079

10.1200/jco.2016.34.15_suppl.tps7079 Get It

Acute leukemia in pregnancy: A single institution experience.
Farhadfar, Nosha , Cerquozzi, Sonia , Michael, Hessenauer R., Letendre, Louis, Litzow, Mark R. , Patnaik, Mrinal M. , Tefferi, Ayalew , Gangat, Naseema , Hogan, William J.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7040-7040

10.1200/jco.2016.34.15_suppl.7040 Get It

Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger
Szuber, Natasha , Vallapureddy, Rangit, Penna, Domenico , Finke, Christy M. , Hanson, Curtis A. , Pardanani, Animesh , Gangat, Naseema , Tefferi, Ayalew , Vallapureddy, Rangit R, Lasho, Terra L. , Gangat, Naseema , Tefferi, Ayalew , Szuber, Natasha , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | August 30, 2018 | Volume: 93 | Issue: 12 | Pages: 1474-1484

10.1002/ajh.25270 | PMID 30157297 Get It

AbstractBetween 1967 and 2017, 361 patients with myeloproliferative neoplasms (MPN), age ≤ 40 years, were seen at our institution, constituting 12% of all MPN patients (n = 3023) seen during the same time period; disease‐specific incidences were 12% in polycythemia vera (PV; n = 79), 20% in essential thrombocythemia (ET; n = 219) and 5% in primary myelofibrosis (PMF; n = 63). Compared to their older counterparts, younger patients were more likely to present with low risk disease (P < .001) and display female preponderance in ET (P = .04), lower incidence of arterial events overall (P < .001), and higher incidence of venous thrombosis in PV (P = .01). Younger patients were also more likely to express CALR mutations, in ET and PMF, normal karyotype, in PV and PMF, and lower incidence of high molecular risk mutations in PMF (P significant in all instances). Over median follow‐up of 11.3, 13, and 7.1 years for PV, ET, and PMF, leukemic transformations were respectively documented in 4%, 2%, and 10% (P values 0.1‐0.9) while incidences of fibrotic progression in PV (22%) and ET (16%) were expectedly higher in young patients, because of their longer survival (P < .001). Median survival in young patients was 37 years for PV, 35 for ET and 20 for PMF; the corresponding values were 22, 22, and 8 years for ages 41‐60 years and 10, 11, and 3 years for ages >60 years (P < .001). Young MPN patients comprise a unique disease subset defined by an attenuated‐risk cytogenetic and mutational backdrop and conspicuously longer survival compared to their older counterparts, which requires assertion during patient counseling.
Practice‐relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm
Tefferi, Ayalew , Shah, Sahrish, Patnaik, Mrinal M. , Reichard, Kaaren K. , Hanson, Curtis A. , Pardanani, Animesh , Lasho, Terra L. , Patnaik, Mrinal , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | August 30, 2018 | Volume: 93 | Issue: 12 | Pages: No page available

10.1002/ajh.25269 | PMID 30156701 Get It

Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome
Benton, Christopher B. , Chien, Kelly S. , Tefferi, Ayalew , Rodríguez, José A. , Kwari, Monica, Pierce, Sherry , Hornbaker, Marisa, Santos, Margarida A. , Siguero, Mariano, Zblewski, Darci, Al‐Kali, Aref , Kantarjian, Hagop M. , Pardanani, Animesh , Garcia‐Manero, Guillermo , Rodriguez, Jose, Ravandi, Farhad , Daver, Naval , Jabbour, Elias , Jain, Nitin , Alvarado, Yesid , Maiti, Abhishek , Aitken, Marisa J.L. , Martinez, Sara, Hogan, William J. , Kantarjian, Hagop

Mayo Clinic

Hematological Oncology | August 30, 2018 | Volume: 37 | Issue: 1 | Pages: 96-102

10.1002/hon.2557 | PMID 30153704 Get It

AbstractTrabectedin is an FDA‐approved DNA minor groove binder that has activity against translocation‐associated sarcomas. Lurbinectedin is a next‐generation minor groove binder with preclinical activity against myeloid leukemia cells. A dose‐finding phase 1 clinical trial was performed in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with further assessment of safety and tolerability. Forty‐two patients with relapsed/refractory AML/MDS received lurbinectedin administered as a 1‐hour intravenous infusion in a 3 + 3 study design. Two dosing schedules were used: 3.5, 5, 7, or 6 mg on days 1 and 8 or 2, 3, 1, or 1.5 mg for 3 consecutive days on days 1 to 3. Three patients experienced dose‐limiting toxicities of rhabdomyolysis (grade 4), hyperbilirubinemia (grade 3), and oral herpes (grade 3) with the day 1 and 8 schedule. Otherwise, adverse events mainly consisted of gastrointestinal manifestations (n = 11), febrile neutropenia/infections (n = 4), pulmonary toxicity (n = 2), and renal failure (n = 2). The most common laboratory abnormalities observed were an increase in creatinine (93%) and anemia, neutropenia, and thrombocytopenia (100%). Overall, 33 of 42 patients (79%) had reduction in blasts in peripheral blood or bone marrow. One patient achieved a partial response and 2 patients a morphologic leukemia‐free state. Most (n = 30, 71%) were discontinued due to progressive disease. Early deaths occurred from disease‐related causes that were not attributable to lurbinectedin. Four patients with a chromosome 11q21‐23 abnormality had significantly greater bone marrow blast reduction than those without such abnormality, with decrease of 31 ± 14% (n = 4) vs 8 ± 8% (n = 16), respectively (P = .04). Overall, lurbinectedin was safe and tolerated using the schedules and dose levels tested. While no sustained remissions were observed, single‐agent lurbinectedin was transiently leukemia suppressive for some patients.